1-22. (canceled)
23. A method for controlling a circuit within a transmitter, the method comprising:
cancelling a zero input offset voltage of a level detector integrated on a chip;
calibrating said level detector over a range of input values utilizing a known temperature independent voltage level; and
controlling an output power of the transmitter based on a corrected level of said level detector.
24. The method according to claim 23, comprising cancelling said zero input offset voltage utilizing a replica bias circuit.
25. The method according to claim 24, comprising combining an output signal from said level detector and an output signal from said replica bias circuit for eliminating said associated zero input offset voltage of said level detector.
26. The method according to claim 24, comprising generating an output signal which is a difference of an output signal from said level detector and an output signal from said replica bias circuit.
27. The method according to claim 24, comprising biasing said level detector and said replica bias circuit utilizing a similar bias voltage.
28. The method according to claim 23, wherein said level detector receives no input ac voltage.
29. A method for controlling a circuit within a transmitter, the method comprising:
cancelling a zero input offset voltage of a level detector integrated on a chip;
calibrating said level detector over a range of input values utilizing a known supply-voltage independent voltage level; and
controlling an output power of the transmitter based on a corrected level of said level detector.
30. The method according to claim 29, comprising cancelling said zero input offset voltage utilizing a replica bias circuit.
31. The method according to claim 30, comprising combining an output signal from said level detector and an output signal from said replica bias circuit for eliminating said associated zero input offset voltage of said level detector.
32. The method according to claim 30, comprising generating an output signal which is a difference of an output signal from said level detector and an output signal from said replica bias circuit.
33. The method according to claim 30, comprising biasing said level detector integrated said on-chip and said replica bias circuit utilizing a similar bias voltage.
34. The method according to claim 29, wherein said level detector receives no input ac voltage.
35. A method for controlling a circuit within a transmitter, the method comprising:
calibrating transmitter output signal strength utilizing an on-chip signal generator and a level detector by comparing a signal generated by said on-chip signal generator to a signal received from an amplifier in the transmitter.
36. The method according to claim 35, comprising buffering an output signal of said on-chip signal generator utilizing CMOS buffers biased with a known reference input voltage.
37. The method according to claim 36, wherein said known reference input voltage is bias-voltage independent.
38. The method according to claim 36, wherein said known reference input voltage is temperature independent.
39. The method according to claim 35, comprising calibrating said transmitter output signal strength at one or more input signal strengths.
40. A system for controlling a circuit within a transmitter, the system comprising:
one or more circuits operable to cancel a zero input offset voltage of a level detector integrated on a chip;
said one or more circuits operable to calibrate said level detector over a range of input values utilizing a known temperature independent voltage level; and
said one or more circuits operable to control an output power of the transmitter based on a corrected level of said level detector.
41. The system according to claim 40, wherein said one or more circuits cancels said zero input offset voltage utilizing a replica bias circuit.
42. The system according to claim 41, wherein said one or more circuits are operable to combine an output signal from said level detector and an output signal from said replica bias circuit to eliminate said associated zero input offset voltage of said level detector.
43. The system according to claim 41, wherein said one or more circuits are operable to generate an output signal which is a difference of an output signal from said level detector and an output signal from said replica bias circuit.
44. The system according to claim 41, wherein said one or more circuits are operable to bias said level detector and said replica bias circuit utilizing a similar bias voltage.
45. The system according to claim 40, wherein said one or more circuits are operable to detect said offset voltage in said level detector with no input ac voltage.
46. A system for controlling a circuit within a transmitter, the system comprising:
one or more circuits operable to cancel a zero input offset voltage of a level detector integrated on a chip;
said one or more circuits operable to calibrate said level detector over a range of input values utilizing a known supply-voltage independent voltage level; and
said one or more circuits operable to control an output power of the transmitter based on a corrected level of said level detector.
47. The system according to claim 46, wherein said one or more circuits are operable to cancel said zero input offset voltage utilizing a replica bias circuit.
48. The system according to claim 47, wherein said one or more circuits are operable to combine an output signal from said level detector and an output signal from said replica bias circuit to eliminate said associated zero input offset voltage of said level detector.
49. The system according to claim 47, wherein said one or more circuits are operable to generate an output signal which is a difference of an output signal from said level detector and an output signal from said replica bias circuit.
50. The system according to claim 47, wherein said one or more circuits are operable to bias said level detector and said replica bias circuit utilizing a similar bias voltage.
51. The system according to claim 46, wherein said one or more circuits are operable to detect said offset voltage in said level detector with no input ac voltage.
52. A system for controlling a circuit within a transmitter, the system comprising:
one or more circuits operable to calibrate transmitter output signal strength utilizing an on-chip signal generator and a level detector by comparing a signal generated by said on-chip signal generator to a signal received from an amplifier in the transmitter.
53. The system according to claim 52, wherein said one or more circuits are operable to buffer an output signal of said on-chip signal generator utilizing CMOS buffers biased with a known reference input voltage.
54. The system according to claim 53, wherein said known reference input voltage is bias-voltage independent.
55. The system according to claim 53, wherein said known reference input voltage is temperature independent.
56. The system according to claim 52, wherein said one or more circuits are operable to calibrate said transmitter output signal strength at one or more input signal strengths.
The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.
1. A sterile pharmaceutical composition for repair of a vascular injury caused by vascular insufficiency in a subject in need thereof comprising:
(a) a therapeutic amount of a sterile chemotactic hematopoietic stem cell product, wherein the therapeutic amount is effective to repair a vascular injury caused by vascular insufficiency, the chemotactic hematopoietic stem cell product comprising a nonexpanded isolated population of autologous mononuclear cells enriched for CD34+ cells, a subpopulation of potent CD34+CXCR-4+ cells that move in response to SDF-1, VEGF or both that have CXCR-4-mediated chemotactic activity, and
(b) a stabilizing amount of serum, wherein the stabilizing amount of serum constitutes from about 0.1% to about 70% (vv) of the composition,
wherein the pharmaceutical composition is formulated for administration parenterally through a catheter; and
is further characterized as having the following properties for at least 24 hours following acquisition of the chemotactic hematopoietic stem cell product when tested in vitro after passage through a catheter:
(i) at least 70% of the cells are CD34+ cells,
(ii) the subpopulation of potent CD34+CXCR-4+ cells that have CXCR-4-mediated chemotactic activity and that move in response to SDF-1, VEGF or both retains its CXCR-4-mediated chemotactic activity;
(iii) at least 70% of the cells are viable; and
(iv) the CD34+ cells is are able to form hematopoietic colonies in vitro,
wherein the stabilizing amount of serum is effective to the CXCR-4 mediated chemotactic activity and hematopoietic colony forming ability of the subpopulation of CD34+CXCR-4+ cells and that move in response to SDF-1, VEGF or both from completion of acquisition from the subject of the nonexpanded isolated population of autologous mononuclear cells to infusion of the composition into the subject.
2. The sterile pharmaceutical composition according to claim 1, wherein the isolated, nonexpanded population of autologous mononuclear cells comprising a subpopulation of CD34+ cells, which further contains a subpopulation of potent CD34+CXCR-4+ cells that have CXCR-4-mediated chemotactic activity and that move in response to SDF-1, VEGF or both is purified from cellular components of a bone marrow aspirate harvested from the subject.
3. The sterile pharmaceutical composition according to claim 1, wherein when the stabilizing amount of serum is at least 10% vv, the sterile pharmaceutical composition is further characterized as having the following properties for at least 48 hours following acquisition of the chemotactic hematopoietic stem cell product when tested in vitro after passage through the catheter:
(a) is capable of forming hematopoietic colonies in vitro; and
(b) retains at least 2% of the chemotactic activity of the CXCR-4-mediated chemotactic activity of the subpopulation of potent CD34+CXCR-4+ cells that have CXCR-4-mediated chemotactic activity.
4. The sterile pharmaceutical composition according to claim 1, wherein when the stabilizing amount of serum is at least 20% (vv), the sterile pharmaceutical composition is further characterized as having the following properties for at least 72 hours following acquisition of the chemotactic hematopoietic stem cell product when tested in vitro after passage through the catheter:
(a) is capable of forming hematopoietic colonies in vitro; and
(b) retains at least 2% of the chemotactic activity of the CXCR-4-mediated chemotactic activity of the subpopulation of potent CD34+CXCR-4+ cells that have CXCR-4-mediated chemotactic activity.
5. The sterile pharmaceutical composition of claim 1, wherein the sterile pharmaceutical composition retains at least 2% of the chemotactic activity-of the CXCR-4-mediated chemotactic activity of the subpopulation of potent CD34+CXCR-4+ cells that have CXCR-4-mediated chemotactic activity and that move in response to SDF-1, VEGF or both for at least 24 hours following acquisition of the chemotactic hematopoietic stem cell product when tested in vitro after passage through the catheter.
6. The sterile pharmaceutical composition according to claim 1, wherein the sterile pharmaceutical composition is formulated for parenteral administration into a coronary blood vessel.
7. The sterile pharmaceutical composition according to claim 1, wherein the catheter is a flow control catheter or a balloon catheter.
8. (canceled)
9. (canceled)
10. The sterile pharmaceutical composition according to claim 1, wherein the sterile pharmaceutical composition is formulated for parenteral administration into myocardium, an artery, a vein, or a muscle.
11-13. (canceled)
14. The sterile pharmaceutical composition according to claim 1, wherein the isolated, nonexpanded population of autologous mononuclear cells comprising a subpopulation of CD34+ cells, which further contains a subpopulation of potent CD34+CXCR-4+ cells that have CXCR-4-mediated chemotactic activity and that move in response to SDF-1, VEGF, or both is purified from peripheral blood collected from the subject.
15. The sterile pharmaceutical composition according to claim 1, wherein the isolated, nonexpanded population of autologous mononuclear cells comprising a subpopulation of CD34+ cells, which further contains a subpopulation of potent CD34+CXCR-4+ cells that have CXCR-4-mediated chemotactic activity and that move in response to SDF-1, VEGF or both is purified from peripheral blood collected from the subject after mobilizing the isolated, nonexpanded population of autologous mononuclear cells using a hematopoietic stem cell mobilizing agent.
16. The sterile pharmaceutical composition according to claim 1, wherein the vascular insufficiency results from occlusion of a coronary artery.
17. The sterile pharmaceutical composition according to claim 16, wherein the vascular insufficiency resulting from occlusion of a coronary artery is a microvascular insufficiency, an ischemia, a transient vascular insufficiency, a chronic ischemia or a myocardial ischemia.
18-21. (canceled)
22. The sterile pharmaceutical composition according to claim 16, wherein the vascular insufficiency resulting from occlusion of a coronary artery produces a myocardial infarction.
23. The sterile pharmaceutical composition according to claim 1, wherein the vascular injury-repairing amount of the chemotactic hematopoietic stem cell product comprises at least 0.5\xd7106 potent CD34+CXCR-4+ cells that have CXCR-4 mediated chemotactic activity and that move in response to SDF-1, VEGF or both.
24. The sterile pharmaceutical composition according to claim 1, wherein the potent CD34+CXCR-4+ cells of the sterile pharmaceutical composition that have CXCR-4-mediated chemotactic activity and that move in response to SDF-1, VEGF or both migrate to and repair damage caused by the vascular insufficiency.
25. The sterile pharmaceutical composition according to claim 24, wherein migration of the potent CD34+CXCR-4+ cells of the sterile pharmaceutical composition that have CXCR-4-mediated chemotactic activity and that move in response to SDF-1, VEGF or both is driven by chemotaxis.
26. The sterile pharmaceutical composition according to claim 25, wherein the chemotaxis is mediated by at least one of SDF-1, VEGF and CXCR-4.
27-55. (canceled)
56. The composition according to claim 15, wherein the hematopoietic stem cell mobilizing agent is G-CSF, GM-CSF or a combination thereof.
57. The composition according to claim 1, wherein the subject is a revascularized subject.
58. The composition according to claim 1, wherein the stabilizing amount of serum is at least 10%.